Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.56 |
| ▸ | FNTB | P49356 | 14/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656457 | 0.94 | FNTA (0.51) | FNTAFNTBPGGT1BCHEK1LIMK1 | |
| SCHEMBL5655111 | 0.89 | FNTA (0.57) | FNTAFNTBPGGT1BCHEK1LIMK1 | |
| SCHEMBL5655089 | 0.89 | FNTA (0.69) | FNTAFNTBPGGT1BCHEK1LIMK1 | |
| Hydrochloric Acid SCHEMBL5658416 | 0.89 | FNTA (0.56) | FNTAFNTBPGGT1BCHEK1LIMK1 | |
| SCHEMBL5658133 | 0.89 | FNTA (0.58) | FNTAFNTBPGGT1BCHEK1LIMK1 | |
| SCHEMBL14588523 | 0.83 | FNTA (0.62) | FNTAFNTBPGGT1BCHEK1LIMK1 | |
| SCHEMBL5656095 | 0.83 | FNTA (0.52) | FNTAFNTBPGGT1BCHEK1LIMK1 | |
| SCHEMBL14588524 | 0.82 | FNTA (0.60) | FNTAFNTBPGGT1B | |
| SCHEMBL1683566 | 0.80 | FNTA (0.79) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL14588558 | 0.79 | FNTA (0.60) | FNTAFNTBPGGT1BRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173040-B2 | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | JANSSEN-CILAG S.A. (FR) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | FNTB, FNTA, CYP7A1 | FNTA 2/4885FNTB 1/4885PGGT1B 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.